Media Articles Related to Lupron (Leuprolide)
WSU researchers show how fatty acids can fight prostate cancer
Source: Nutrition / Diet News From Medical News Today [2015.03.20]
Mechanism points way to more effective drug treatmentWashington State University researchers have found a mechanism by which omega-3 fatty acids inhibit the growth and spread of prostate cancer...
Study identifies 'lethal' subtype of prostate cancer
Source: Genetics News From Medical News Today [2015.03.19]
7,500 deaths per year possibly due to MAP3K7-CHD1 lossA University of Colorado Cancer Center study published in the journal Cancer Research defines a new, distinct subtype of "lethal" prostate...
Predicting prostate cancer
Source: Prostate / Prostate Cancer News From Medical News Today [2015.03.19]
Nanotechnology shows promise for more accurate prostate cancer screening and prognosisA Northwestern University-led study in the emerging field of nanocytology could one day help men make better...
Inappropriate breast, prostate cancer imaging 'may be driven by regional factors'
Source: Breast Cancer News From Medical News Today [2015.03.15]
Regional culture and infrastructure may be behind high rates of inappropriate breast and prostate cancer imaging, finds a new study.
VolitionRx initiates second prostate cancer pilot study assessing Nucleosomics(R) technology
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.03.10]
VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has initiated a pilot...
Published Studies Related to Lupron (Leuprolide)
A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. [2011.09]
PURPOSE: We investigated the efficacy and safety of degarelix treatment and the effects of switching from leuprolide to degarelix in an ongoing extension study with a median 27.5-month followup of a pivotal 1-year prostate cancer trial... CONCLUSIONS: Data support the statistically significant prostate specific antigen progression-free survival benefit for degarelix over leuprolide seen during year 1 and the use of degarelix as first line androgen deprivation therapy as an alternative to a gonadotropin-releasing hormone agonist. Copyright (c) 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
A randomized trial of microdose leuprolide acetate protocol versus luteal phase ganirelix protocol in predicted poor responders. [2011.06.30]
We performed a randomized trial to compare IVF outcomes in 54 poor responder patients undergoing a microdose leuprolide acetate (LA) protocol or a GnRH antagonist protocol incorporating a luteal phase E(2) patch and GnRH antagonist in the preceding menstrual cycle.
Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide. [2011.06]
The aim of the study was to compare the onset, incidence and frequency/intensity of hot flushes during androgen-deprivation therapy with a gonadotropin-releasing hormone antagonist (GnRH) blocker versus an agonist using data from a randomized Phase 3 clinical trial...
Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. [2011.04]
OBJECTIVE: To compare the efficacy of leuprolide and continuous oral contraceptives in the treatment of endometriosis-associated pain...
Effects of metformin and leuprolide acetate on insulin resistance and testosterone levels in nondiabetic postmenopausal women: a randomized, placebo-controlled trial. [2010.11]
OBJECTIVE: To determine whether insulin sensitizers lower androgen levels and whether androgen suppression improves insulin resistance in nondiabetic postmenopausal women... They confirm that treatment of insulin resistance decreases T production in this population and demonstrate that pharmacologic lowering of T does not affect insulin resistance.
Clinical Trials Related to Lupron (Leuprolide)
Pharmacodynamics of Lorelin Depot (Leuprorelin Acetate - Bergamo) Compared to Lupron Depot ï¿½ (Leuprorelin Acetate - Abbot) [Recruiting]
The primary objective of this study is to examine, in healthy subjects, the comparative
pharmacodynamics of Lorelin Depot (leuprorelin), manufactured by the Chemical
Pharmaceutical Laboratory Bergamo Ltda with the product Lupron Depot ® (leuprorelin),
manufactured by Abbott Laboratories Ltd, through the strength of biological markers follicle
stimulating hormone (FSH), luteinizing hormone (LH) and total testosterone, associated with
the activity of the substance.
Secondarily be observed safety (tolerability) of subjects in clinical research through the
comparison of clinical and laboratory parameters pre-and post-study, and incidence of
Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer [Recruiting]
The purpose of this research study is to determine the effects of abiraterone acetate plus
leuprolide acetate and prednisone versus leuprolide acetate alone on hormone levels in the
blood and prostate. For this study, patients are required to be suitable candidates for a
radical prostatectomy (prostate surgery) which will be performed after 24 weeks of
Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg) [Recruiting]
(A) Major 1) to compare the effectiveness of norethindrone acetate (NA) with GnRH agonist
(Lupron-Depot-3) in relieving symptoms of endometriosis, 2) to compare bone density in the
two treated groups in order to demonstrate that NA does not affect bone density; (B) Minor:
1) To compare the lipid profiles of patients in the two groups to confirm the hypothesis
that the effects of NA and GnRH agonists on lipid profiles are similar, 2) To determine
whether quality of life, assessed by questionnaire, is better in patients assigned to NA
than in patients assigned to GnRH, 3) To determine whether NA has fewer adverse effects than
Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide [Recruiting]
The purpose of this study is to determine if patients initiating androgen deprivation
therapy (ADT) for prostate cancer can be transitioned from degarelix acetate to leuprolide
acetate after an initial three-month period without a rise in serum testosterone. The
investigators expect testosterone will quickly and reliably reach castrate levels after
initiation of ADT and will remain castrate during the transition, and there will be no
"testosterone surge" after leuprolide injection.
Ipilimumab + Androgen Deprivation Therapy in Prostate Cancer [Recruiting]
The goal of this clinical research study is to learn if ipilimumab in combination with
either Lupron® (leuprolide), Zoladex® (goserelin), or Firmagon® (degarelix) can affect
prostate-specific antigen (PSA) levels in patients with prostate cancer. Researchers also
want to learn if these drug combinations affect the body's immune system. The safety of
these drug combinations will also be studied.
Reports of Suspected Lupron (Leuprolide) Side Effects
Hot Flush (12),
Night Sweats (8),
Abortion Spontaneous (8),
Back Pain (8),
Bone Pain (7), more >>